[ad_1]
BEIJING, KOMPAS.com – Indonesia, Brazil and Turkey will be the recipient countries for China’s corona vaccine if they have truly passed the third phase of clinical trials.
When the country is also the site of the third phase of clinical trials of the candidate corona virus vaccine developed by Sinovac Biotech.
Reporting from Sputnik News via CalledOn Friday (9/25/2020), SinoVac Biotech CEO Yin Weidong said his party had started the third phase of clinical trials in all three countries.
The timing of the start of the phase three clinical trial was Brazil on July 21, Indonesia on August 1, and Turkey on September 16.
Also read: Sinovac’s optimistic Corona virus vaccine is ready in early 2021
“We have also received approval for clinical trials in Bangladesh … The first batch will be distributed on a priority basis in China, and in parallel in countries with clinical trials, specifically Brazil, Indonesia and Turkey,” Yin said.
Yin added that the vaccine candidate named CoronaVac has built a factory to increase vaccine production capacity.
If the factory is completed, the vaccine production capacity will multiply to 3 million doses in one year.
Yin rejected the request Sputnik News to mention the candidate’s estimated cost for the corona virus vaccine.
Also Read: Spanish Newspapers Report Chinese Hackers Stealing Corona Vaccine Data
He reasoned that the price of the vaccine would depend on a variety of factors.
Reported Kompas.com Previously, Sinovac Biotech said that CoronaVac should be ready for worldwide distribution by early 2021.
This was announced by the company on Thursday (9/24/2020).
Also read: Trump: April 2021 All American citizens can receive Corona vaccines
Yin promised to submit an application to the United States Food and Drug Administration (FDA) to sell CoronaVac in the United States if it passes the third phase of clinical trials.
“At first, our strategy was designed for China and Wuhan. Immediately after that, in June and July, we adjusted our strategy for the world,” Yin said as reported. ABC News.
